Wouter N Leonhard
Overview
Explore the profile of Wouter N Leonhard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1016
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kanhai A, Sanchez-Lopez E, Kuipers T, van Klinken J, Dijkstra K, van der Veen I, et al.
iScience
. 2023 Nov;
26(11):108278.
PMID: 38026227
Metabolic reprogramming is a driver of autosomal dominant polycystic kidney disease (ADPKD) progression and a potential therapeutic intervention route. We showed before that the AMP-associated protein kinase (AMPK) activator salsalate...
2.
Song X, Leonhard W, Kanhai A, Steinberg G, Pei Y, Peters D
Front Mol Biosci
. 2023 Feb;
10:1058825.
PMID: 36743216
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disorder and an important cause of end stage renal disease (ESRD). Tolvaptan (a V2R antagonist) is the first disease...
3.
Kramers B, Koorevaar I, van Gastel M, Goor H, Hallows K, Heerspink H, et al.
Clin J Am Soc Nephrol
. 2022 Mar;
17(4):507-517.
PMID: 35314480
Background And Objectives: The vasopressin V2 receptor antagonist tolvaptan is the only drug that has been proven to be nephroprotective in autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan also causes...
4.
Kanhai A, Bange H, Verburg L, Dijkstra K, Price L, Peters D, et al.
Sci Rep
. 2020 Feb;
10(1):1672.
PMID: 32015419
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common monogenic disorders, characterized by the progressive formation of fluid-filled cysts. Tolvaptan is an approved drug for ADPKD patients,...
5.
Malas T, Leonhard W, Bange H, Granchi Z, Hettne K, van Westen G, et al.
EBioMedicine
. 2019 Dec;
51:102585.
PMID: 31879244
Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common causes of end-stage renal failure, caused by mutations in PKD1 or PKD2 genes. Tolvaptan, the only drug...
6.
Leonhard W, Song X, Kanhai A, Iliuta I, Bozovic A, Steinberg G, et al.
EBioMedicine
. 2019 Sep;
47:436-445.
PMID: 31473186
Background: Multiple preclinical studies have highlighted AMP-activated protein kinase (AMPK) as a potential therapeutic target for autosomal dominant polycystic kidney disease (ADPKD). Both metformin and canagliflozin indirectly activate AMPK by...
7.
Booij T, Leonhard W, Bange H, Yan K, Fokkelman M, Plugge A, et al.
J Mol Cell Biol
. 2019 May;
12(8):644-653.
PMID: 31065693
Polycystic kidney disease (PKD) is a prevalent genetic disorder, characterized by the formation of kidney cysts that progressively lead to kidney failure. The currently available drug tolvaptan is not well...
8.
Shi H, Leonhard W, Sijbrandi N, van Steenbergen M, Fens M, van de Dikkenberg J, et al.
J Control Release
. 2018 Nov;
293:113-125.
PMID: 30472374
The aim of the present study was to develop folic acid (FA) conjugates which can deliver the kinase inhibitor dactolisib to the kidneys via folate receptor-mediated uptake in tubular epithelial...
9.
Kunnen S, Malas T, Formica C, Leonhard W, t Hoen P, Peters D
Biomed Pharmacother
. 2018 Oct;
108:1123-1134.
PMID: 30372813
Mutations in the PKD1 or PKD2 genes are the cause of autosomal dominant polycystic kidney disease (ADPKD). The encoded proteins localize within the cell membrane and primary cilia and are...
10.
Verschuren E, Mohammed S, Leonhard W, Overmars-Bos C, Veraar K, Hoenderop J, et al.
Am J Physiol Renal Physiol
. 2018 May;
315(3):F537-F546.
PMID: 29767557
The PKD1 gene encodes polycystin-1 (PC1), a mechanosensor triggering intracellular responses upon urinary flow sensing in kidney tubular cells. Mutations in PKD1 lead to autosomal dominant polycystic kidney disease (ADPKD)....